Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20219104 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL20835164 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL22401146 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL23437458 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL20882132 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL23437576 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL22401186 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL23437461 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL22096531 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL6718103 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655715-A | Stabilized RSV F proteins and uses thereof | 默沙东公司 | 2020-09-11 | — | — | CN | claimed |
| CN-103167866-B | For the novel low molecular weight amount cation lipid of oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-09-23 | — | — | CN | claimed |
| CN-103167866-A | Novel low molecular weight cationic lipids for oligonucleotide delivery | MERCK SHARP & DOHME | 2013-06-19 | — | — | CN | claimed |
| EP-4630057-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | Recode Therapeutics, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4590282-A1 | LIPID NANOPARTICLE WITH NUCLEIC ACID CARGO | NovoArc GmbH (AT) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025137646-A1 | GENE EDITING METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | RECODE THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025029927-A1 | LIPID NANOPARTICLE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-02-06 | — | — | WO | disclosed |
| CN-118251498-A | Gene constructs for expression of MRNA | 基因特力株式会社 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024123633-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-117836002-A | Hepatitis c virus immunogenic compositions and methods of use thereof | 奥罗拉疫苗有限责任公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024062001-A1 | LIPID NANOPARTICLE WITH NUCLEIC ACID CARGO | NOVOARC GMBH (AT) | 2024-03-28 | — | — | WO | disclosed |
| CN-112220797-A | C/EBP alpha compositions and methods of use | 米纳治疗有限公司 | 2021-01-15 | — | — | CN | disclosed |
| CN-112236134-A | Carotenoid compositions and uses thereof | L.E.A.F.控股集团公司 | 2021-01-15 | — | — | CN | disclosed |
| EP-2937369-B1 | QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT, AND USE FOR SAID CATALYST | TOSOH CORP (JP) | 2020-11-11 | — | — | EP | disclosed |
| CN-107075515-B | C/EBP alpha compositions and methods of use | 米纳治疗有限公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-111655715-A | Stabilized RSV F proteins and uses thereof | 默沙东公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20150344727-A1 | QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT AND USE THEREOF | TOSOH CORPORATION (JP) | 2015-12-03 | — | — | US | disclosed |
| EP-2937369-A1 | QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT, AND USE FOR SAID CATALYST | Tosoh Corporation (JP) | 2015-10-28 | — | — | EP | disclosed |
| CN-103167866-B | For the novel low molecular weight amount cation lipid of oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-09-23 | — | — | CN | disclosed |
| CN-103167866-A | Novel low molecular weight cationic lipids for oligonucleotide delivery | MERCK SHARP & DOHME | 2013-06-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344727-A1 | QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT AND USE THEREOF | CA2, KCNMB1, BET1 | TSHR 2952/4885THRB 1663/4885LMNA 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.